At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 1, 2026 at 21:31 ET
Telix announced FDA alignment to proceed to Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, following successful review of safety data from Part 1. The FDA agreed on the clinical protocol and statistical plan, allowing US enrollment to begin upon IND amendment submission. This regulatory milestone de-risks the pivotal trial and supports TLX591-Tx's differentiated profile with no observed kidney toxicity.
- FDA confirmed Part 1 safety data sufficient to start Part 2 of ProstACT Global trial in the US.
- TLX591-Tx (177Lu rosopatamab tetraxetan) targets PSMA in metastatic castration-resistant prostate cancer.
- Two-dose regimen administered 14 days apart, combined with abiraterone, enzalutamide, or docetaxel.
- TLX591-Tx shows no significant kidney toxicity and minimal salivary/lacrimal uptake vs. other PSMA-targeted radioligand therapies.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access